Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with rela…

B-cell Non-Hodgkins Lymphoma (B-NHL)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT05685173

A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment

Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional sam…

Hairy Cell Leukemia (HCL)Chronic Lymphocytic Leukemia (CLL)Non-Hodgkins Lymphoma (NHL)+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT01087333

Phase 2

A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).

The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients …

T-Prolymphocytic LeukemiaNon-Hodgkins Lymphoma

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Ascentage Pharma Group Inc.NCT04496349

Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic l…

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT04728893

Phase 2

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab Monotherapy and Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) proﬁle for gloﬁtamab in combination with gemcitabine and oxaliplatin (Glo…

Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Hoffmann-La RocheNCT06806033

Phase 2

Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TB…

Acute LeukemiaAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia+25 more

Estimated

~$75 – $2,000